Company / Total Assets
BioXcel Therapeutics, Inc. Total Assets History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$44.9M
FY2025
5-year range
$38.3M / $205.9M
FY2022-FY2025
Trend
+17.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets returned to growth in FY2025 after 2 years of decline, reaching $45M.
Based on SEC 10-K filings.
$45M in FY2025 with a 3-year CAGR of -39.8%.
Declined from $74M to $45M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -39.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -39.8%, indicating a declining trend.
- In FY2025, total assets increased 17.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.9M | +17.2% |
| FY2024 | $38.3M | -48.0% |
| FY2023 | $73.7M | -64.2% |
| FY2022 | $205.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026